Adaptimmune Therapeutics (ADAP) Announces Proposed 12.5M ADS Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/6/2026
- S&P, Dow futures steady as MidEast deal in focus; chip, software stocks tumble
- Sandisk unveils underwhelming outlook despite AI demand surge; shares slip
- Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- SoftBank secures $10 billion loan backed by OpenAI stake
- Salesforce president Srini Tallapragada steps down, becomes advisor
- Sandisk (SNDK) Tops Q4 EPS by $4.66, Offers Guidance
- EverCommerce names Alex Goor as new CEO, founder steps down
- Crude Inventory Rose 2.5 Million Barrels Last Week - EIA
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
Adaptimmune Therapeutics (ADAP) Prices 20.5M ADS Offering at $11/ADS
June 2, 2020 5:52 AM EDTAdaptimmune Therapeutics plc (NASDAQ: ADAP) today announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares (ADSs) at a price to the public of $11.00 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase... More
Jones Trading Upgrades Adaptimmune Therapeutics plc (ADAP) to Buy
May 29, 2020 2:41 PM EDTJones Trading analyst Soumit Roy upgraded Adaptimmune Therapeutics plc (NASDAQ: ADAP) from Hold to Buy.
For an analyst ratings summary and ratings history on Adaptimmune Therapeutics plc click here. For more ratings news on Adaptimmune Therapeutics plc click here.
Shares of Adaptimmune Therapeutics plc closed at $4.86 yesterday.
... MoreMizuho Said Adaptimmune Therapeutics plc (ADAP) ASCO Data 'Incrementally Supportive'
May 29, 2020 1:13 PM EDTMizuho Securities analyst Mara Goldstein reiterated a Neutral rating and $3.00 price target on Adaptimmune Therapeutics plc (NASDAQ: ADAP), but said ASCO data was "incrementally supportive, acceleration of Synovial Sarcoma trial."
The analyst commented, "ADAP reported a substantial data update this morning via... More
Adaptimmune (ADAP) Announces SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction, Lung, and Head and Neck Cancers
May 29, 2020 7:33 AM EDTAdaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology (ASCO) Annual Meeting. The data demonstrate durability and responses in synovial sarcoma, supporting SPEARHEAD-1 as a potential registrational trial. The ASCO presentation also describes a new response in a patient with lung cancer, and a response in a patient with head and neck cancer (reported in January).
The Company also announced new responses in the SURPASS trial, confirming the potential for... More
